Iterum Therapeutics plc
Develops novel oral & IV anti-infectives to combat multi-drug resistant pathogens.
ITRM | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 3 DUBLIN LANDINGS, DUBLIN 1
- Website:
- https://www.iterumtx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing and commercializing differentiated anti-infectives to address the global crisis of multi-drug resistant (MDR) pathogens. The company's primary focus is on its lead product, sulopenem, a novel penem antibiotic available in both oral and intravenous (IV) formulations. Sulopenem is designed to treat infections caused by MDR gram-negative bacteria in both hospital and community settings, aiming to provide a new, effective treatment option for physicians and patients facing the challenge of antibiotic resistance.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Iterum Therapeutics plc filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Iterum Therapeutics plc
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Iterum Therapeutics plc via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
